relapsed and refractory adult invasive B cell lymphoma
Conditions
Interventions
Case series:CART cell sequential treatment
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Confirmation of a recurrent refractory invasive B-cell lymphoma with a positive target marker (a lymphoma cell expressing a therapeutic target antigen such as CD19, CD22, CD20) (standard reference NCCN guidelines, 5th edition, 2017); Recurrent invasive B-cell lymphoma refers to patients with invasive B-cell lymphoma who have re-emerged with increased tumor burden after CR, and refractory invasive B-cell lymphoma refers to invasive B cells that have not reached CR after 4 cycles of standard chemotherapy. Lymphoma patients. 2. Patients must have evaluable disease certificates, including minimal residual disease; 3. Aged 18-70 years old; 4. Estimated survival period of more than 3 months; 5. ECOG score 0-2 points; 6. Women of childbearing age are negative for the blood pregnancy test before the start of the trial and agree to take effective contraceptive measures during the trial period until the last follow-up.
Exclusion criteria
Exclusion criteria: 1. Primary central nervous system invasive B-cell lymphoma or invasive B-cell lymphoma involving the central nervous system; 2. History of epilepsy or other central nervous system disorders; 3. Active hepatitis B or hepatitis C virus infection, HIV, cytomegalovirus, EB virus infection or other unhealed active infections; 4. Pregnant or lactating women; 5. Those who have used any gene therapy product before; 6. Any situation that the investigator believes may increase the risk of the subject or interfere with the results of the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ratio of bone marrow and peripheral B leukemia cells; | — |
Countries
China
Contacts
Public ContactXiaoyan Ke
Beijing Boren Hospital
Outcome results
None listed